H.C. Wainwright analyst Robert Burns raised the firm’s price target on ArriVent Biopharma (AVBP) to $40 from $39 and keeps a Buy rating on the shares following the Q1 report
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent BioPharma Advances Cancer Pipeline in Q1 2025
- ArriVent BioPharma: Promising Clinical Developments and Strategic Advancements Justify Buy Rating
- ArriVent Biopharma reports Q1 EPS ($1.90), consensus (69c)
- ArriVent Biopharma sees cash, equivalents funding operations into 2H26
- ArriVent BioPharma Appoints Merdad Parsey as New Director